<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01130324</url>
  </required_header>
  <id_info>
    <org_study_id>0113</org_study_id>
    <nct_id>NCT01130324</nct_id>
  </id_info>
  <brief_title>VIBATIV Pregnancy Registry</brief_title>
  <official_title>VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to&#xD;
      VIBATIV at any time during pregnancy. There are no mandated physician visits for the&#xD;
      registry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Released by he FDA from this Post-Marketing Commitment&#xD;
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">October 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Outcomes of pregnancy in women exposed to VIBATIV at any time during pregnancy</measure>
    <time_frame>Once per trimester, 6-7 months gestation, and within 4 weeks after the estimated due date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of fetal exposure to VIBATIV on pregnancy outcomes</measure>
    <time_frame>Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal/neonatal outcomes</measure>
    <time_frame>Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant development and milestones through 12 months of age</measure>
    <time_frame>Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>VIBATIV treated pregnant women</arm_group_label>
    <description>Women treated with telavancin (any dose or duration) during pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIBATIV</intervention_name>
    <description>Observational</description>
    <arm_group_label>VIBATIV treated pregnant women</arm_group_label>
    <other_name>telavancin</other_name>
    <other_name>TD-6424</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women exposed to VIBATIV during pregnancy and where outcome of pregnancy is unknown at time&#xD;
        of enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients who were exposed to VIBATIV at any time during pregnancy&#xD;
&#xD;
          -  Outcome of pregnancy is unknown at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Haberle, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cumberland Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cumberland Pharmaceuticals Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VIBATIV</keyword>
  <keyword>telavancin</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Registry</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telavancin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

